CD274 and neoplasm: Resistance to programmed‐death‐1/programmed‐death‐ligand‐1 (PD‐1/PD‐L1) blockade in non‐small‐cell lung cancer (NSCLC) arises mainly from weak tumor immunogenicity and limited effector T‐cell infiltration.